The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
New Therapies Requiring Ultra Large Scale Monoclonal Ab Production In Microalgae
Funder
National Health and Medical Research Council
Funding Amount
$630,089.00
Summary
Monoclonal antibodies target pathogens and molecules with exquisite specificity, and are essential for therapeutics and diagnostics. They are currently made using high-tech/limited-capacity mammalian cell cultures which limit them to low-dose applications. We aim to enable new, high-dose antibody therapies (e.g. antiviral treatments, passive immunisation) via rapid, low-cost, dramatically larger-scale production of valuable medicinal antibodies in a photosynthetic-driven, green algae system.
Monoclonal antibodies, such as the cancer therapeutic Pembrolizumab, have revolutionised the treatment of cancer and many inflammatory conditions. With over $100 billion in sales in 2018, they also underpin a growing biotech industry. We have developed a highly specific, high affinity therapeutic antibody candidate, and demonstrated efficacy in animal models of malignancy. This project will advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
The Development Of Store Operated Calcium Channel Monoclonal Antibody Inhibitors As A Therapeutic Option For Breast Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$230,753.00
Summary
Despite recent advances in the treatment of breast cancer, a significant proportion of women with this disease receive little benefit from currently available treatments and die from breast cancer. Hence, new therapies for the breast cancers with the poorest prognosis are needed. This grant exploits our earlier finding that a specific calcium channel is a likely therapeutic target for breast cancer. Funding from this grant will be used to develop an inhibitory monoclonal antibody to this target.
Developing New Immunotherapeutics Through Studying Immune Effectors In Situ
Funder
National Health and Medical Research Council
Funding Amount
$1,369,054.00
Summary
The immune system deploys pore forming proteins to clear viral and bacterial infections and to eliminate cancerous cells. The unwanted activities of these molecules, however, results in chronic disease and in transplant rejection. We aim to understand how pore forming immune weapons interact with our own cells, with the goal of using this information to develop new approaches to treat immune driven disease and to improve the success of transplantation therapy.
Development Of Antibodies To Il-13 Receptor And Their Preclinical Testing In A Sheep Model For Human Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$435,375.00
Summary
The increasing prevalence and severity of asthma worldwide highlights the need for novel approaches to treat this disease. This proposal will generate antibodies that can be used to specifically block the action of a key molecule known to regulate many of the hallmark features of asthmatic disease. Preclinical evaluation of these antibodies in an established sheep model of human asthma will allow their assessment as a specific therapy for asthma.